Loading…
Abbott has agreed to acquire Bigfoot Biomedical, a developer of smart insulin management systems. The transaction is expected to close in Q3 2023; financial terms were not disclosed.
Abbott and Bigfoot Biomedical announced an agreement to develop and commercialize diabetes management systems integrating Abbott's FreeStyle Libre glucose sensing technology with Bigfoot's insulin delivery solutions in the United States.